Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018: Highlights

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 612
Rating:

Prof Gordon McVie , Will Davies

Prof Gordon McVie, Kings College London, and ecancer Medical Reporter Will Davies discuss the headlines and highlights of ESMO 2018 in Munich.

Find all this news and more in our conference coverage.
 


Head and Neck
Impassion 130: PD1 Immunotherapy for breast cancer
PALOMA 3: Palbociclib in HR HER2- breast cancer
Chidamide in 2nd line breast cancer
Erlotinib superior to gemcitabine for EGFR NSCLC
JAVELIN: Avelumab and axitinib for kidney cancer
GETUG 12 trial for localised high risk prostate cancer
SOLO1: Olaparib maintenance for ovarian cancer
Checkmate 142: Combination immunotherapy for mCRC
Biosimilar Symposium
Women4Oncology Award


For more on the breast cancer news from the conference, Dr Matteo Lambertini offered his highlights.

For key data from melanoma trials, Dr Teresa Amaral summarised key sessions from the conference.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation